Latest Allergic conjunctivitis Stories
IRVINE, Calif., Oct. 15 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced it will release third quarter 2010 financial results after market close on November 2, 2010. In conjunction, the Company will host a conference call at 4:30 p.m.
IRVINE, Calif., Oct. 6 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 27 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today highlighted results from the Company's REMURA(TM) (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.
ANTONY, France, September 6, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. has announced today the signing of exclusive partnership agreements with Shionogi & Co., Ltd.
IRVINE, Calif., Sept. 1 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will present at the Stifel Nicolaus Healthcare Conference 2010 at 11:30 a.m. Eastern Time on September 16, 2010, in Boston, MA.
IRVINE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) ("ISTA"), today reported financial results for the quarter ended June 30, 2010. Second quarter 2010 net revenues were $35.1 million, an increase of 46% from the second quarter of 2009.
IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc.
ANTONY, France, June 28, 2010 /PRNewswire-FirstCall/ -- After having announced positive results for the first year of its phase IIb/III clinical trial (VO 57.07) conducted on Actair(R) sublingual allergen immunotherapy tablets in allergic rhinitis triggered by house dust mites in April 2009, Stallergenes S.A.
LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Data published at the European Allergy, Asthma & Clinical Immunology (EAACI) congress in London today documents that GRAZAX(R) is the only allergy immunotherapy tablet (AIT) to show sustained disease control 2 years after treatment completion.
SAN FRANCISCO, May 3 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).
- The parings of haberdine; also, any kind of fragments.